The CHARISMA study: In search of the best antiplatelet strategy for cardiovascular prevention;L'étude CHARISMA: À la recherche de la meilleure stratégie antiagrégante plaquettaire en prévention cardio-vasculaire

Revue Medicale de Liege

Volumn 61, Issue 9, 2006, Pages 656-661

  Scheen, A J ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabétologie Nutrition et Maladies Métaboliques   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antiplatelet agent; Aspirin; Cardiovascular prevention; Clopidogrel; Combined therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PROPHYLAXIS; STROKE; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 33749631232     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hermans C, Brohet Ch.- La thérapeutique antiplaquettaire. In: Athérosclérose Athérothrombose (Eds: Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 212-229.
2. Antithrombotic Trialists' Collaboration.- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J, 2002, 324, 71-86.
3. Pearson TA, Steven N, Blair SN, et al.- American Heart Association guidelines for primary prevention of cardiovascular disease and stroke. Circulation, 2002, 106, 388-391.
4. Patrono C, Bachmann F, Baigent C, et al.- Expert consensus document on the use of antiplatelet agents. Eur Heart J, 2004, 25, 166-181.
5. Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C.- Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005, 353, 2373-2383.
6. Kulbertus H.- L'aspirine: acquisitions récentes en prévention cardiovasculaire. Rev Med Liège, 2004, 59, 695-703.
7. Scheen AJ, Lefèbvre PJ, Kulbertus H.- Comment je préviens ... Les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une "polypill"? Rev Med Liège, 2003, 58, 527-533.
8. Patrono C.- Insulin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost, 2003, 1, 1710-1713.
9. Hanjis C, Frishman WH, Lerner RG.- Aspirin resistance: mechanisms and clinical implications. Cardiol Rev, 2006, 14, 18-25.
10. Jarvis B, Simpson K.- Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs, 2000, 60, 347-377.
11. Hirsch J, Bhatt DL.- Comparative benefits of clopidogrel and aspirin in high-risk patient populations. Arch Intern Med, 2004, 164, 2106-2110.
12. CAPRIE Steering Committee.- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
13. Bhatt DL, Fox KAA, Hacke W, et al.- Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354, 1706-1717.
14. Scheen AJ.- Comment j'explore ... les critères de jugement dans les essais cliniques: réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège, 2006, 61, 260-266.
15. Scheen AJ.- L'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde: entre deux idées de l'idéal. Rev Med Liège, 2006, 61, 53-59.
16. Scheen AJ, Lefèbvre PJ.- L'étude PROactive: prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
17. Pfeffer MA, Jarcho JA.- The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med, 2006, 354, 1744-1746.
18. Radermecker RP, Scheen AJ.- L'étude FIELD de protection cardio-vasculaire avec le fénofibrate chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 957-961.
19. Evangelista V, Totani L, Rotondo S, et al.- Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. Thromb Haemost, 2005, 93, 8-16.
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.- Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 2005, 54, 2430-2435.
21. Legrand DA, Scheen AJ.- L'aspirine en prévention primaire des maladies cardio-vasculaires chez le patient diabétique: différence sexuelle et résistance à l'aspirine. Rev Med Liège, 2006, 61, sous presse.
22. Wang TH, Bhatt DL, Topol EJ.- Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J, 2006, 27, 647-54.